Role of the lysophosphatidylinositol/GPR55 axis in cancer

Marco Falasca; Riccardo Ferro

doi:10.1016/j.jbior.2015.10.003

Role of the lysophosphatidylinositol/GPR55 axis in cancer

Adv Biol Regul. 2016 Jan:60:88-93. doi: 10.1016/j.jbior.2015.10.003. Epub 2015 Oct 28.

Authors

Marco Falasca¹, Riccardo Ferro²

Affiliations

¹ Metabolic Signalling Group, School of Biomedical Sciences, CHIRI Biosciences, Curtin University, Perth, Western Australia 6102, Australia; Queen Mary University of London, Barts and The London School of Medicine and Dentistry, Blizard Institute, 4 Newark Street, London E1 2AT, UK. Electronic address: marco.falasca@curtin.edu.au.
² Queen Mary University of London, Barts and The London School of Medicine and Dentistry, Blizard Institute, 4 Newark Street, London E1 2AT, UK.

PMID: 26588872
DOI: 10.1016/j.jbior.2015.10.003

Abstract

Lysophosphatidylinositol (LPI) is a well-known bioactive lipid that is able to activate signalling cascades relevant to cell proliferation, migration, survival and tumourigenesis. It is well-established that the G protein-coupled receptor 55 (GPR55) is the specific receptor for LPI. Several investigations have demonstrated that the signalling pathways activated by LPI through its receptor GPR55 play a pivotal role in different cancer type. This review focuses on the role of the LPI/GPR55 axis, in particular with regards to its pharmacological potential therapeutic exploitation.

Keywords: ABC transporters; Cancer; Cannabidiol; G protein-coupled receptor 55; LPI.

Publication types

Research Support, Non-U.S. Gov't
Review

MeSH terms

Animals
Carcinogenesis
Humans
Lysophospholipids / metabolism*
Receptors, Cannabinoid
Receptors, G-Protein-Coupled / genetics
Receptors, G-Protein-Coupled / metabolism*
Signal Transduction

Substances

GPR55 protein, human
Lysophospholipids
Receptors, Cannabinoid
Receptors, G-Protein-Coupled
lysophosphatidylinositol

Abstract

Publication types

MeSH terms

Substances

Grants and funding